DNA Biomed Valuation
| DNA Stock | ILS 88.60 1.60 1.84% |
At this time, the firm appears to be overvalued. DNA Biomed Solns owns a latest Real Value of S66.87 per share. The recent price of the firm is S88.6. Our model computes the value of DNA Biomed Solns from reviewing the firm fundamentals such as EBITDA of 18.42 M, shares owned by insiders of 54.87 %, and Return On Asset of -0.0375 as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that DNA Biomed's price fluctuation is very steady at this time. Calculation of the real value of DNA Biomed Solns is based on 3 months time horizon. Increasing DNA Biomed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since DNA Biomed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DNA Stock. However, DNA Biomed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 88.6 | Real 66.87 | Hype 88.6 | Naive 96.33 |
The real value of DNA Stock, also known as its intrinsic value, is the underlying worth of DNA Biomed Solns Company, which is reflected in its stock price. It is based on DNA Biomed's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of DNA Biomed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of DNA Biomed Solns helps investors to forecast how DNA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DNA Biomed more accurately as focusing exclusively on DNA Biomed's fundamentals will not take into account other important factors: DNA Biomed Total Value Analysis
DNA Biomed Solns is currently forecasted to have takeover price of 59.57 M with market capitalization of 86.46 M, debt of 0, and cash on hands of 492 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the DNA Biomed fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
59.57 M | 86.46 M | 0 | 492 K |
DNA Biomed Asset Utilization
One of the ways to look at asset utilization of DNA is to check how much profit was generated for every dollar of assets it reports. DNA Biomed Solns owns a negative utilization of current and long term assets of -0.0375 %, losing S3.75E-4 for each shekel of current and long term assets held by the firm. Inadequate asset utilization denotes the company is being less productive with each shekel of current and long term assets it owns. Strictly speaking, asset utilization of DNA Biomed Solns shows how discouraging it operates for each shekel spent on its current and long term assets.DNA Biomed Ownership Allocation
DNA Biomed Solns secures a total of 123.16 Million outstanding shares. DNA Biomed Solns shows considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.DNA Biomed Profitability Analysis
Net Income was 18.37 M with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates DNA Biomed's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in DNA Biomed and how it compares across the competition.
About DNA Biomed Valuation
The stock valuation mechanism determines DNA Biomed's current worth on a weekly basis. Our valuation model uses a comparative analysis of DNA Biomed. We calculate exposure to DNA Biomed's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of DNA Biomed's related companies.D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
8 Steps to conduct DNA Biomed's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates DNA Biomed's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct DNA Biomed's valuation analysis, follow these 8 steps:- Gather financial information: Obtain DNA Biomed's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine DNA Biomed's revenue streams: Identify DNA Biomed's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research DNA Biomed's industry and market trends, including the size of the market, growth rate, and competition.
- Establish DNA Biomed's growth potential: Evaluate DNA Biomed's management, business model, and growth potential.
- Determine DNA Biomed's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate DNA Biomed's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for DNA Stock analysis
When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |